Home > News > Headline News > Archive

Click on title to read the full article.

Genentech’s Kadcyla Helped People With Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New P

September 27, 2013

By Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Kadcyla® (ado-trastuzumab emtansine) significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival [PFS], a co-primary endpoint) compared to people who received a treatment of their physician’s choice in an open-label Phase III study called TH3RESA.

New knowledge on molecular mechanisms behind breast cancer

September 26, 2013

Researchers at University of Copenhagen have gained more insight into the molecular mechanisms of importance for, for example, cancer cell growth and metastasis.

Metastatic breast cancer - 'it's like getting all four tires flattened'

September 19, 2013

By Claudia Feldman, Houston Chronicle

Lori's complete story: Parts 1 and 2

Lori Sumako was your perfect, stage 1 breast cancer patient.

She followed all of her doctor's orders. She endured the surgery and chemotherapy without (too many) complaints. She and husband Rick Mitchell gave thanks for each year that she was cancer-free.

FDA approves Teva's generic version of Roche cancer drug Xeloda

September 18, 2013

The US Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of Roche Holding AG's cancer drug Xeloda.

Breakthrough Designation Granted to Entinostat for Advanced Breast Cancer

September 11, 2013

By OncLive

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced estrogen receptor (ER)-positive breast cancer.

Managing Bone Health in Metastatic Breast Cancer

September 6, 2013

By OncLive

Two agents, denosumab (Xgeva) and zoledronic acid (Zometa), are currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).

Aggressive breast cancer may be sensitive to drugs attacking their waste disposal

September 4, 2013

By Oncology Nurse Advisor

Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome.